Schneider Wallace is representing two occupational and physical therapists in their potential class action against Cantex Continuing Care Network, for allegations of unpaid forced overtime. Cantex Continuing Care is headquartered in Texas with skilled nursing facilities, rehabilitation, home health, hospice and assisted living facilities in Texas, Louisiana and New Mexico. 

Over 1,200 nurses represented by Schneider Wallace Cottrell Konecky requested a federal judge grant class certification to their allegations of unpaid wages at Arnot Health New York hospitals. The nurses claim automatic deductions for breaks occurred even as they worked through meals and breaks.

Schneider Wallace Cottrell Konecky LLP, a national plaintiff side law firm, is pleased to announce the March 14, 2022 opening of its new office in Los Angeles, California. The firm’s new office – its second in California and fifth nationwide – will focus on complex litigation involving employment, consumer protection, and antitrust matters. The Los Angeles office, located on 300 S. Grand Avenue, is within walking distance to both state and federal courthouses.

On February 10, 2022, the U.S. District Court for the Southern District of New York preliminarily approved a class settlement between Blue Cross and Blue Shield of Minnesota, on behalf of a putative class of health care payors, and Vyera and two of its executives, including Martin Shkreli, over their alleged anticompetitive conduct to protect exorbitant price increases for Daraprim.

On February 14th, 2022, the Security and Exchange Commission (SEC) revealed BlockFi had agreed to a $100 million settlement for failing to register their crypto lending products and for violations of the Investment Company Act of 1940 and Securities Act of 1933.

On January 27, 2022, the U.S. District Court for the District of Connecticut gave preliminary approval to a $420 million all-cash deal to settle claims from a class of investors over misrepresentations related to the value of Teva’s generics drug business, which has been the subject of numerous investigations and lawsuits over far-reaching market allocation and price fixing practices.

On January 14, 2022, United States District Court Judge Denise Cote ordered Martin Shkreli to pay a total of $64.6 million to seven states defrauded by Shkreli’s pharmaceutical company, Vyera, through its illegal pricing scheme for the drug Daraprim.  These states include New York, California, Ohio, Pennsylvania, Illinois, North Carolina and Virginia.  Judge Cote further ordered an injunction forever banning Shkreli from participating “in any capacity” in the pharmaceutical industry.

Schneider Wallace Cottrell Konecky represented plaintiffs in two of the 10 largest California class action settlements of 2020, and one of the largest 10 in the nation in 2020, according to legal verdict and settlement list makers. 

Schneider Wallace is an experienced California employment class action law firm, able to assist with wage and hour disputes, unpaid overtime, discrimination, harassment, or other employment matters. Our experienced team of trial lawyers has more than 20 years of experience litigating complex employment cases and achieving the best possible recovery for our clients.

Printer workers from Segerdahl Corp. won class certification for their claim executives of the company violated federal law when they sold the company for less than it was worth. Judge Andrea Wood approved the class certification on June 16th, 2020, for allegations that the executives pocketed a large portion of the $265 million paid for the company.

ERISA, or the Federal Employee Retirement Income Security Act, imposes strict duties on those responsible for administering retirement plan assets. Limiting fees and costs is one of the duties of the fiduciary, and allegations of $100m plus set aside for bonuses and other forms of executive compensation could violate ERISA.

On December 9, 2021 Judge Troy L. Nunley of the U.S. District Court for the Eastern District of California temporarily blocked implementation of California’s California Assembly Bill 824, legislation that imposes restrictions on “pay for delay” settlements in pharmaceutical litigation, including the greater of $20 million or three times the affected commerce.